title: Could ceftaroline be an alternative therapy for linezolid resistant Staphylococcus epidermidis infections in Intensive Care Medicine?
abstract: BACKGROUND
  Coagulase negative Staphylococcus continues generating interest in critically ill patients, due to their infections in extended admissions, in instrumented patients and due to their described multidrug resistance, which include glycopeptide heterorresistance and the increase in oxazolidinone resistance. Ceftaroline is a new cephalosporin with activity against resistant gram-positives, which, being betalactam, may provide adequate safety profile in the critical ill patient. The aim of this study was to determine the activity of ceftaroline and other antimicrobial agents against methicillin and linezolid-resistant Staphylococcus epidermidis.
  
  
  METHODS
  We studied susceptibility of ceftaroline, tigecycline, daptomycin and vancomycin in a total of sixty-eight methicillin and linezolid-resistant S. epidermidis isolates with clinical significance from an Intensive Care Unit, using E-test.
  
  
  RESULTS
  All strains were susceptible to the four antimicrobial agents, regardless of the level of resistance to linezolid.
  
  
  CONCLUSIONS
  Ceftaroline could be an alternative in the treatment of methicillin and linezolid-resistant S. epidermidis infections in critically ill patients.
authors.affiliation: Francisco Javier Candel González, Department of Clinical Microbiology and Infectious Diseases Hospital Clínico San Carlos, Madrid, Spain. fj.candel@gmail.com.
authors.forename: Francisco Javier
authors.initials: FJ
authors.lastname: Candel
authors.forename: Elvira
authors.initials: E
authors.lastname: Baos
authors.forename: Mercedes
authors.initials: M
authors.lastname: Nieto
authors.forename: Juan José
authors.initials: JJ
authors.lastname: Picazo
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000382:microbiology; D001826:Body Fluids / Q000382:microbiology; D055499:Catheter-Related Infections / Q000382:microbiology; D002511:Cephalosporins / Q000494:pharmacology* / Q000627:therapeutic use; D003422:Critical Care; D003428:Cross Infection / Q000188:drug therapy*; D017576:Daptomycin / Q000494:pharmacology; D024901:Drug Resistance, Multiple, Bacterial; D005122:Exudates and Transudates / Q000382:microbiology; D006801:Humans; D000069349:Linezolid / Q000494:pharmacology* / Q000627:therapeutic use; D008712:Methicillin / Q000494:pharmacology / Q000627:therapeutic use; D008911:Minocycline / Q000031:analogs & derivatives / Q000494:pharmacology; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013212:Staphylococcus epidermidis / Q000187:drug effects* / Q000302:isolation & purification; D000078304:Tigecycline; D014640:Vancomycin / Q000494:pharmacology; D000097583:Ceftaroline
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D017576:Daptomycin; D000069349:Linezolid; D008712:Methicillin; D008911:Minocycline; D000078304:Tigecycline; D014640:Vancomycin; D000097583:Ceftaroline